Eszopiclone(ess zop’ ah klone)
LunestaDNC
PREGNANCY CATEGORY C
CONTROLLED SUBSTANCE C-IV
Drug Classes
Nonbenzodiazepine hypnotic
Sedative-hypnotic
Therapeutic Actions
Exact mechanism of action is not known. It is thought to interact with GABA receptors at binding domains near benzodiazepine receptor sites, leading to sedation.
Indications
Treatment of insomnia
Contraindications and Cautions
Contraindicated with known hypersensitivity to components of drug.
Use cautiously with geriatric or debilitated patients, diseases or conditions that could affect metabolism or hemodynamics, signs or symptoms of depression, impaired respiratory function, hepatic impairment, pregnancy, lactation; history of substance abuse (may be habit-forming).
Available Forms
TabletsDNC—1, 2, 3 mg
Dosages
Adult
Initial dose—2 mg PO taken immediately before bedtime. Dosage may be increased to 3 mg PO immediately before bedtime if clinically needed. The tablet should be swallowed whole, not cut or crushed. Avoid taking with meals.
Pediatric patients
Safety and efficacy not established.
Geriatric patients
Initial dose—1 mg PO taken immediately before bedtime if the primary complaint is falling asleep. If the primary complaint is difficulty staying asleep, 2 mg PO immediately before bedtime may be used.
Patients with severe hepatic impairment
1 mg PO immediately before bedtime. Use caution and monitor the patient closely.
Patients concurrently using CYP3A4 inhibitors
1 mg PO immediately before bedtime. May be increased to 2 mg with caution.
